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Abstract
Background: Studies on HPV infection in pregnant women and HPV transmission to the child
have yielded inconsistent results.
Methods: To estimate mother-to-child HPV transmission we carried out a prospective cohort
study that included 66 HPV-positive and 77 HPV-negative pregnant women and their offspring
attending a maternity hospital in Barcelona. To estimate HPV prevalence and genotype distribution
in pregnancy we also carried out a related screening survey of cervical HPV-DNA detection among
828 pregnant women. Cervical cells from the mother were collected at pregnancy (mean of 31
weeks) and at the 6-week post-partum visit. Exfoliated cells from the mouth and external genitalia
of the infants were collected around birth, at the 6-week post-partum visit, and around 3, 6, 12,
and 24 months of age. All samples were tested for HPV using PCR. Associations between potential
determinants of HPV infection in pregnant women and of HPV positivity in infants were also
explored by logistic regression modelling.
Results: Overall cervical HPV-DNA detection in pregnant women recruited in the HPV screening
survey was 6.5% (54/828). Sexual behavior-related variables, previous histories of genital warts or
sexually transmitted infections, and presence of cytological abnormalities were statistically
significantly and positively associated with HPV DNA detection in pregnant women recruited in the
cohort. At 418 infant visits and a mean follow-up time of 14 months, 19.7% of infants born to HPV-
positive mothers and 16.9% of those born to HPV-negative mothers tested HPV positive at some
point during infants' follow-up. The most frequently detected genotype both in infants and mothers
was HPV-16, after excluding untyped HPV infections. We found a strong and statistically significant
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BMC Infectious Diseases 2009, 9:74 http://www.biomedcentral.com/1471-2334/9/74association between mother's and child's HPV status at the 6-week post-partum visit. Thus,
children of mothers' who were HPV-positive at the post-partum visit were about 5 times more
likely to test HPV-positive than children of corresponding HPV-negative mothers (p = 0.02).
Conclusion: This study confirms that the risk of vertical transmission of HPV genotypes is
relatively low. HPV persistence in infants is a rare event. These data also indicate that vertical
transmission may not be the sole source of HPV infections in infants and provides partial evidence
for horizontal mother-to-child HPV transmission.
Background
Despite the overwhelming evidence for a sexual transmis-
sion of high-risk HPVs, other routes of transmission have
been proposed. Several studies have explored whether
HPVs can be vertically transmitted from mother to child
by direct contact during labor, or horizontally through
manipulation of the child with infected hands, bathing,
towels and fomites (reviewed in [1,2]). Studies evaluating
transmission of HPV from mother to infant and HPV per-
sistence in newborns and children are conflicting and
show a wide range of rates. Furthermore, a number of
studies report HPV-DNA detection in infants born to
HPV-DNA negative mothers. Thus, the mode of HPV
acquisition in children, including vertical and horizontal
transmission, remains a controversial issue [3].
To assess in a low-risk country the prevalence and deter-
minants of HPV infection in pregnant women as well as
perinatal transmission and persistence of HPV types, we
carried out an HPV screening survey in pregnant women
and a prospective study of HPV-positive and HPV-nega-
tive mothers and their infants.
Methods
Recruitment of subjects
The project was initiated in 1995 by carrying out a pro-
spective cohort study of pregnant women attending a
public maternity hospital for prenatal care in urban Barce-
lona, Spain. The hospital covers mostly general, non-
selected population in its catchment area. Pregnant
women were selected according to their potential risk of
HPV exposure as based on their history of high-risk sexual
behavior, genital warts, abnormal colposcopy, and HPV-
related cervical lesions by cytology or histology. Emphasis
was placed in recruiting high-risk women to procure a
high yield of HPV-positive mothers and thus increase sta-
tistical power to properly study HPV transmission. A total
of 115 consenting pregnant women were included and
classified according to their risk of HPV exposure into
high- (n = 73) and low-risk (n = 42) groups. At their first
or second obstetric visit (mean pregnancy time 32.1
weeks, rank 30 to 34 weeks), consenting women were
tested for cervical HPV-DNA status using a screening con-
sensus primer PCR (see below). Since the yield of HPV-
positive pregnant women was too low (4 of 42 women
and 24 of 73 women from the low- and high-risk group,
respectively) to adequately assess mother-to-child HPV
transmission, we extended the study by carrying out an
HPV screening survey among unselected pregnant women
to identify and recruit additional HPV-positive subjects
for the prospective cohort study.
HPV screening survey among unselected pregnant women
Subjects for this HPV screening survey included 858 preg-
nant women consecutively attending the prenatal care
clinic of the maternity hospital between 1997 and 2000.
Consenting women were tested for cervical HPV-DNA sta-
tus at their obstetric visit (mean pregnancy time 31 weeks,
rank 29 to 33 weeks) using the same consensus primer
PCR (see below) as that used in the initial cohort study.
Women were included in the prospective cohort study
only when a positive result was found (i.e. HPV-negative
pregnant women from this HPV screening survey were not
included in the prospective cohort study). Participation
rates were not estimated and refusals were replaced by the
next consenting women. This limitation should not bias
our results as the purpose of the HPV screening survey was
mainly the recruitment of additional HPV positive preg-
nant women to the prospective cohort study. Thirty
women were excluded because the cervical samples col-
lected were invalid for PCR testing leaving a total number
of 828 women for the analysis of HPV prevalence among
unselected pregnant women. Women from this survey
that were not recruited into the prospective cohort study
(those testing HPV-negative) did not receive the risk-fac-
tor questionnaire (see below).
Prospective cohort study
Women in the final prospective cohort study included
those from the initial cohort (n = 115) and all HPV-positive
women from the HPV screening survey (n = 54) along with
their offspring. At the enrollment visit, performed between
2 and 12 weeks after the HPV screening visit, all 169
women signed a written informed consent and were
administered a full standardised questionnaire by personal
interview that included socioeconomic, reproductive, sex-
ual behavior, and risk factor variables. A standardised clin-
ical form was also used to systematically collect all relevant
clinical parameters during pregnancy, labor, and follow up
visits. The questionnaires and clinical forms were only col-Page 2 of 12
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cohort study but not for the group of women that tested
HPV-negative in the HPV screening survey.
Cervical samples and follow-up
Cervical samples from each woman were collected using a
dry swab (Eurotubo® collection swab, Spain), at two time
points: at the pregnancy visit (mean pregnancy times:
32.1 weeks for women in the initial cohort; and 31 weeks
for women in the HPV screening survey), and at the 6-
week postpartum visit. All samples were screened for cyto-
logical abnormalities.
Mouth and anogenital exfoliated cells from all infants
were collected for HPV-DNA detection, using the same
device as that used for mothers, at or around birth
(between 0 and 6 days), at or around 6 weeks, and at or
around 3, 6, 12, and 24 months of age. Genital samples
from boys were obtained by gently rubbing the penis
glans and the inner mucosal part of the prepuce. The
penile shaft was not sampled. Genital samples from girls
were obtained by gently rubbing throughout the mucosal
part of the vulva. Mouth samples were obtained by firmly
rubbing the dors of the tongue, mucosal part of the cheeks
and the hard palate, using a single swab. Particular care
was taken with sample collection procedures to prevent
cross-contamination between subjects and different ana-
tomical sites by using disposable equipment and chang-
ing bed lining and gloves for each woman. All the samples
from recruited infants were mostly collected by the same
pediatrician (JMP) throughout the study. Since the initial
anal specimens did not yield sufficient DNA for adequate
HPV testing, collection of anal samples was discontinued
early in the follow-up and the few results obtained for this
site were not considered in our analyses. All samples were
sent to the laboratory, suspended in 1 mL of 0.1 M PBS
(phosphate buffered saline), transferred to clean sterile
eppendorf tubes and kept frozen at -20°C until processed.
At each visit a physical examination of the child that
included also a clinical inspection of the oral cavity and
the external anogenital area was performed.
HPV-DNA detection and genotyping
DNA extraction was performed using 200 μL of cervical or
oral cells suspensions and 400 μL from genital cells using
the Qiamp Viral DNA kit (QIAGEN, Hilden, Germany) in
accordance with the manufacturer's instructions.
Amplification was performed using 5 μL extracted DNA
with the consensus primers MY09/MY11, which amplify a
fragment from the L1 HPV gene [4]. PCR was performed
in 50 μL of reaction mixture containing 2.2 mM MgCl2,
10 mM Tris HCl, 50 mM KCl, 2 μM of dNTPs, 1 μM of d-
UTP-digoxigenin (DIG), 25 pmol of each primer and 1 U
of Taq polimerase (Roche Diagnostics S.L.). PCR was car-
ried out with the following cycling parameters: 95°C 1
min, 55°C 1 min, and 72°C 1 mim for 40 repeating
cycles. PC04/GH20 primers were used to amplify a frag-
ment of the Human β-globin gene as internal control of
DNA integrity and absence of PCR inhibitors [5]. Generic
HPV and type-specific biotinylated probes were immobi-
lised on a strepavidin-coated microtiter plate. DIG-
labeled PCR products were denatured, hybridised under
stringent conditions, and detected using peroxidase-con-
jugated anti-digoxigenin antibody with colorimetric sub-
strate. PCR products positive with the generic probe
hybridization were also tested with HPV 6, 11, 16, 18, 31,
33 and 39 specific probes to asses type-specific positivity.
Positive samples by the generic probe that failed to
hybridize type-specific probes were classified as untyped
and labeled HPV X.
All specimens were processed blindly to child or mother
HPV-risk or HPV DNA initial status. Each PCR run
included DNA extraction and HPV negative controls. Par-
ticular care was taken to prevent carry-over contamination
by separating pre- and post-PCR areas.
Statistical analyses
HPV prevalence was estimated among women at the preg-
nancy visit and at the 6-week postpartum visit. HPV prev-
alence estimates in pregnant women did not include
those in the initial cohort study as these women were
selected according to their risk of HPV exposure and
would yield an overestimated HPV prevalence. Determi-
nants of both HPV positivity in pregnant women and in
their offspring were explored by multivariate uncondi-
tional logistic regression models to estimate prevalence
odds ratios (ORs) and 95 percent confidence limits. ORs
where adjusted by age in tertiles (<29, 29–33, >33). Even
though these women were selected based on their HPV
status and thus biased towards HPV positivity, this should
not affect the validity of exploring potential risk factors for
HPV infection in pregnant women.
HPV prevalence in infants and mother to child transmis-
sion rates were estimated at the perinatal period (0 to 6
days of life), at the 6-week postpartum visit and, since few
HPV positive samples were detected after the 6-week visit,
all childrens' HPV results from successive visits (3 months
throughout 24 months) were combined in one single
prevalence estimate. Overall and type-specific HPV trans-
mission rates were also estimated at any point during fol-
low-up. Estimates are given according to the HPV status of
the mother at pregnancy and at the 6-week postpartum
visit. HPV type-specific concordance among paired
mother-child samples was estimated among the HPV-pos-
itive samples that could be genotyped. Paired samples
with HPV X were not counted as concordant.Page 3 of 12
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sion: HPV positivity rates in infants born to HPV-negative
mothers, and the correlation between HPV status in the
mother and HPV status in the child in paired mother-
child samples simultaneously collected at the 6-week visit.
All women participating in the cohort study signed a writ-
ten informed consent. Protocols were approved by the
local ethical committees of the Maternity Hospital, where
the study was carried out, and the Ciutat Sanitaria i Uni-
versitaria de Bellvitge, where the coordinating center of
the study was located.
Results
HPV detection among pregnant women
Of the initial 169 recruited pregnant women (115 from
the initial cohort and 54 from the HPV screening survey),
82 (28 from the initial cohort and 54 from the HPV
screening survey) were HPV positive at the pregnancy
visit. The genotype distribution in these HPV-positive
samples from pregnant women was in descending order
of frequency: HPV 16 (32.9%), HPV X (28.0%), HPV 6/11
(25.6%), HPV 31 (11.0%), HPV 39 (9.8%), HPV 18
(7.3%), HPV 33 (3.7%). Multiple types were present in 14
women (17.1%). The most frequent combinations among
these were co-infection of HPV 16 with other types
(50.0%) and co-infection of HPV 31 with HPV 39
(35.7%). Cervical HPV prevalence in the unselected group
of pregnant women from the HPV screening survey was
6.5% (54/828; 95% CI: 4.9%–8.4%).
Baseline characteristics of subjects in the cohort
Of the initial 169 recruited women with a known HPV-
DNA status, 26 mother-infant pairs (16 from the initial
cohort and 10 from the HPV screening survey) were
excluded from the prospective cohort study because no
adequate sample from the child could be obtained for
HPV testing neither at birth nor at any of the subsequent
follow-up visits. Of the 26 excluded pairs, 16 (6 from the
initial cohort and 10 from the HPV screening survey) were
HPV positive. The distribution of HPV types in these 16
excluded HPV-positive women did not statistically differ
from the 66 HPV-positive women finally included in the
cohort (p = 0.23). Thus, the final prospective cohort study
included 143 mother-infant pairs with a valid PCR result.
A total of 418 study visits were performed with a mean fol-
low-up time of 14 months. All pregnancies ended on sin-
gle births.
The characteristics of the 143 women and infants enrolled
in the prospective cohort study along with the obstetric
clinical details are detailed in Table 1.
As shown in Table 2 of the 143 pregnant women included
in the cohort, 46.2% (66/143) tested positive for HPV-
DNA during pregnancy. Excluding untyped infections,
HPV 16 singly (25.8%) or in combination with other
types (10.6%) was the most frequently detected type, fol-
lowed by HPV 6/11 (15.2%), HPV 31 singly or with other
types (9.1%), HPV 18 (6.1%), HPV 33 singly or with other
types (3%), and HPV 39 (1.5%). The proportion of
untyped infections (HPV X) was 28.8%.
Determinants of HPV infection in pregnant women in the 
cohort
The age-adjusted analyses to identify determinants of cer-
vical HPV infection in pregnant women yielded the
expected pattern of established risk factors for HPV infec-
tion (Table 3). No associations were found with marital
status, tobacco smoking, parity, OC use and dietary varia-
Table 1: Baseline characteristics of the 143 women included in 
the prospective cohort study.
Characteristics Number
(n = 143)
%
Age
≤ 25 22 15.4
26–30 45 31.5
31–35 52 36.4
≥ 36 24 16.8
Marital status
Married 99 69.2
Cohabiting 37 25.9
Single 2 1.4
Separated 5 3.5
Number of previous pregnancies
0 46 32.2
1 47 32.9
2 34 23.8
3 11 7.7
≥ 4 5 3.5
Parity
0 65 45.5
1 53 37.1
2 22 15.4
3–4 3 2.1
Weeks of pregnancy at delivery
≤ 37 13 9.1
38–39 80 55.9
≥ 40 50 35.0
Type of delivery
Eutocic 86 60.1
Instrumental 38 26.6
Cesarean section 19 13.3
Duration of delivery (hours)
< 1 13 9.1
1–5 75 52.4
6–10 47 32.9
>10 8 5.6
Fetal stress during labor
Yes 11 8.0
No 127 92.0
Unknown 5Page 4 of 12
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before age 20, a history of previous STDs, and, to a lesser
extent, an early age at first sexual intercourse, were the
determinants most strongly related to HPV-DNA detec-
tion during pregnancy.
As expected we found a strong association between HPV
positivity and presence of cervical lesions (LSIL or worse).
All HSIL cases tested HPV positive being HPVs 16, 18, and
HPV X the most frequently detected types among women
with HSIL.
HPV positivity in infants
At 418 infant visits and a mean follow-up time of 14
months, overall prevalence of HPV in infants at any visit
was 18.2% (Table 2). The most frequently detected types in
infants after excluding untyped infections were HPV 16,
followed by HPV 6/11 and HPV 18 and 31. HPV positivity
Table 2: HPV results in mothers and infants included in the prospective cohort study.
Number
(n = 143)
% (95% CI)
Mothers' HPV-DNA status at pregnancy
Positive/Tested 66/143 46.2 (37.8–54.7)
Type distribution among HPV positive:
HPV 6,11 10 15.2
HPV 16 17 25.8
HPV 18 4 6.1
HPV 31 1 1.5
HPV 33 1 1.5
HPV 39 1 1.5
HPV 16 + other types 7 10.6
HPV 31 + other types 5 7.6
HPV 33 + other types 1 1.5
HPV X 19 28.8
Mothers' HPV-DNA prevalence at 6 weeks postpartum
Positive/Tested 25/118 21.2 (14.2–29.7)
Type distribution among HPV positive:
HPV 6,11 4 16.0
HPV 16 8 32.0
HPV 18 2 8.0
HPV 16 + other types 2 8.0
HPV 18 + other types 1 4.0
HPV 31 + other types 2 8.0
HPV 39 + other types 1 4.0
HPV X 5 20.0
Infants' HPV-DNA positivity (positive/tested)
Between 0 and 6 days 7/117 6.0 (2.4–11.9)
6 weeks after birth 14/110 12.7 (7.1–20.4)
Between 3 and 24 months 8/88 9.1 (4.0–17.1)
At any point (0 to 24 months) 26/143 18.2 (12.2–25.5)
Type distribution among HPV positive (at any point during follow-up):
HPV X 10 38.5
HPV 16 8 30.8
HPV 6/11 6 23.1
HPV 18 1 3.8
HPV 31 1 3.8
Infants' HPV positivity by mother's HPV-DNA status (positive/tested)
Born to HPV negative mothers 13/77 16.9 (9.3–27.1)
Born to HPV positive mothers 13/66 19.7 (10.9–31.3)
Origin of HPV positive samples in children
Oral 16 51.6
Genital 15 48.4Page 5 of 12
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Table 3: Selected determinants of HPV infection in pregnant women recruited in the prospective cohort study.
HPV
Positive/tested
(n = 66/143)
HPV-positive
(%)
OR (95% CI)
Age
≤ 20 3/4 75.0 1.0 Reference
21–25 10/18 55.6 0.42 (0.04–4.82)
26–30 17/45 37.8 0.20 (0.02–2.11)
31–35 21/52 40.4 0.23 (0.02–2.32)
≥ 36 15/24 62.5 0.56 (0.05–6.19)
Chi-square p-value 0.16
Marital Status
Married 41/99 41.4 1.0 Reference
Cohabiting 20/37 54.1 1.78 (0.81–3.90)
Single 1/2 50.0 1.62 (0.10–27.30)
Separated 4/5 80.0 4.09 (0.42–40.26)
Chi-square p-value 0.25
Age at first intercourse
≤ 17 27/42 64.3 1.0 Reference
18–19 yrs 15/35 42.9 0.38 (0.15–1.00)
≥ 20 yrs 13/37 35.1 0.29 (0.11–0.76)
Unknown 11/29
Chi-square p-value 0.03
No. of sexual partners before 20 years of age
0 5/24 20.8 1.0 Reference
1 29/58 50.0 3.45 (1.12–10.67)
≥ 2 21/32 65.6 7.23 (2.05–25.50)
Unknown 11/29
Chi-square p-value 0.004
Lifetime no. of sexual partners
1 17/44 38.6 1.0 Reference
2–4 17/39 43.6 1.22 (0.50–2.95)
≥ 5 21/31 67.7 3.17 (1.19–8.41)
Unknown 11/29
Chi-square p-value 0.04
Previous history of genital warts
No 28/70 40.0 1.0 Reference
Yes 23/39 59.0 2.15 (0.96–4.82)
Unknown 15/34
Chi-square p-value 0.06
Previous history of STD
No 37/92 40.2 1.0 Reference
Yes 14/17 82.4 6.82 (1.82–25.62)
Unknown 15/34
Chi-square p-value 0.001
Cytology results
Normal 49/120 40.8 1.0 Reference
ASCUS 1/1 100 1.0
≥ LSIL 12/17 70.6 3.15 (1.03–9.61)
Unknown 4/5
Chi-square p-value 0.02
Models adjusted by age (≤ 28, 29–33, ≥ 34 years)
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ples were collected: 51.6% versus 48.4% of the oral and
genital specimens were positive for HPV-DNA, respectively.
HPV status concordance between oral and genital samples
was 93%. Of the 26 infants that tested HPV positive at any
point during follow-up, a valid PCR result from both the
oral and the genital sites was obtained in 26 pairs. In 24 of
these oral-genital pairs the HPV status was discordant, in
one pair the detected types were concordant for HPV 11
and in the other pair the types were not concordant.
Determinants of HPV infection in children
Table 4 summarizes the results of the analyses exploring
putative risk factors for HPV infection in children at any
time during follow-up. None of the clinical, obstetric and
sexual behavior-related characteristics of the mother was
associated with HPV detection in the children. The only
determinants associated with HPV-DNA detection in the
offspring were the mother's HPV status at the postpartum
visit and, inversely, mother's past use of hormonal contra-
ception. Thus, at the 6-week post-partum visit, children of
mothers who were HPV-positive at the post-partum visit
were about 5 times more likely to test HPV-positive than
children of corresponding HPV-negative mothers (27.3%
vs. 7.2%, respectively; age-adjusted OR = 4.8; 95% CI,
1.4–16.9; p = 0.02). Mothers testing HPV positive both at
the pregnancy visit and at the post-partum visit, were
twice more likely than mothers testing negative at both
visits to have HPV-positive children at any time during
follow-up (29.2% versus 15.4%, respectively: age-
adjusted OR = 2.3, 95% CI, 0.8–7.1). However, the
increased risk didn't reach statistical significance.
Mother to child HPV transmission
As shown in Table 5, 19.7% of the 66 infants born to HPV-
positive mothers and 16.9% of the 77 infants born to
HPV-negative mothers tested HPV-DNA positive at some
point during follow-up (p = 0.7). As also shown in Table
4, we found a statistically significant association between
HPV status in mothers' and children's samples collected at
the 6-week visit: 27.3% versus 7.2%, respectively (p =
0.02). We also found an association between mother's
HPV status at the post-partum visit and infant's HPV pos-
itivity at any time during follow-up (p = 0.03). There was
no association between mother's HPV status at pregnancy
and child's HPV status at any of the follow-up visits. Table
5 also shows that the type-specific concordance in paired
mother-child samples was low at any of the visits. The
overall distribution of HPV types among mothers at preg-
nancy was not statistically significantly different from that
among infants at any time (p = 0.80)
HPV persistence in mothers and infants
A total of 118 women had valid PCR results both at preg-
nancy and at the post-partum visit. Among women HPV-
positive at pregnancy HPV status persistence up to the
post-partum visit was 46.2% (24/52). New infections at
the post-partum visit among HPV-negative women at
pregnancy occurred in only one woman (1.5%, 1/66).
Thus, there was a strong association between HPV status
at pregnancy and HPV status in the mother at the post-
partum visit (p < 0.0001). Type-specific concordance
among HPV-positive women between pregnancy and
post-partum visit was 100% (17/17 after excluding 7
women with HPV X at either visit). The overall type-spe-
cific distribution of HPV-positive mothers at pregnancy
was not statistically significantly different from that at the
post-partum visit (p = 0.83). Of the 19 mothers that tested
HPV X at pregnancy only 2 were HPV X persistent at the
post-partum visit, 9 became HPV negative, 3 became
HPV-16 positive, and in the remaining 5, no PCR result
was available at the post-partum visit.
Of the 26 children that tested HPV positive at some point
during follow-up, 18 had at least two consecutive samples
to assess HPV persistence. Three (16.7%) had two consec-
utive HPV-positive samples and in two of them (11.1%)
there was genotype-specific persistence. In the remaining
15 infants (83.3%) their first HPV-positive sample was
followed by a subsequent HPV-negative sample. There
was no statistical evidence that the distribution of HPV
types detected from the infants changed over time (data
not shown). At the end of the study none of the infants
developed oral, anogenital or cutaneous, macroscopically
identifiable HPV-related lesions.
Discussion and Conclsusion
Our data from both the HPV screening survey of unse-
lected pregnant women and the prospective cohort study
provide for the first time estimates for HPV prevalence,
type-specific distribution, mother-to-child transmission
rates as well as HPV persistence in pregnant women and
in infants in Spain.
Consistent with previous reports (reviewed in [2,3,6-8]),
our data confirm that the risk of transmission of any HPV
type from infected mothers to the newborn is shown to be
relatively low (9.4%), even lower (2.0%) if type-specific
transmission is considered.
Although HPV-DNA detection rates in samples of new-
borns and infants vary widely in the literature, well con-
ducted prospective studies suggest that the risk of
perinatal transmission, although existent, is relatively
low. Several studies have tested infants for HPV-DNA or
antibodies ([9-13] and reviews [2,3,6-8]). Detection rates
in the first 1 or 2 days of life range between 4% and 72%
among infants born to women with genital HPV detected
during pregnancy, and between 0.6% and 20% among
infants delivered by women with no detectable HPV dur-Page 7 of 12
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Mother's and pregnancy characteristics HPV
Positive/Tested
HPV-positive children
(%)
OR (95% CI)
Total 26/143 18.2%
Age at delivery
<26 5/22 22.7 1.0 Reference
26–30 9/45 20.0 0.85 (0.25–2.93)
31–35 8/52 15.4 0.62 (0.18–2.16)
>35 4/24 16.7 0.68 (0.16–2.94)
Chi-square p-value 0.87
Weeks of pregnancy at delivery
<38 3/13 23.1 1.0 Reference
38–39 15/80 18.8 0.77 (0.19–3.14)
>39 8/50 16.0 0.64 (0.14–2.84)
Chi-square p-value 0.82
Type of delivery
Eutocic 12/86 14.0 1.0 Reference
Instrumental 10/38 26.3 2.20 (0.85–5.68)
Cesarean section 4/19 21.1 1.60 (0.45–5.75)
Chi-square p-value 0.24
Duration of delivery (hours)
<1 3/13 23.1 1.0 Reference
1–5 13/75 17.3 0.71 (0.17–2.97)
6–10 7/47 14.9 0.60 (0.13–2.83)
>10 3/8 37.5 2.10 (0.28–15.57)
Chi-square p-value 0.46
Marital status
Married or Cohabiting 25/136 18.4 1.0 Reference
Single or Separated 1/7 14.3 0.78 (0.09–7.10)
Chi-square p-value 0.78
Age at first intercourse
≤ 17 9/42 21.4 1.0 Reference
18–19 7/35 20.0 0.89 (0.28–2.79)
≥ 20 6/37 16.2 0.67 (0.21–2.20)
Unknown 4/29
Chi-square p-value 0.84
Number of previous pregnancies
0 9/46 19.6 1.0 Reference
1 8/47 17.0 0.89 (0.31–2.61)
2 5/34 14.7 0.79 (0.22–2.79)
≥ 3 4/16 25.0 1.69 (0.35–8.29)
Chi-square p-value 0.83
Lifetime no. of sexual partners
1 9/44 20.5 1.0 Reference
2–4 8/39 20.5 1.01 (0.35–2.94)
≥ 5 5/31 16.1 0.76 (0.23–2.57)
Unknown 4/29
Chi-square p-value 0.87
Previous history of STD
No 15/92 16.3 1.0 Reference
Yes 5/17 29.4 2.19 (0.67–7.16)
Unknown 6/34
Chi-square p-value 0.20
Hormonal contraceptive use
Never 10/26 38.5 1.0 Reference
Ever 12/88 13.6 0.24 (0.09–0.67)
Unknown 4/29
Chi-square p-value 0.005
Tobacco smoking status
Never smoker 7/33 21.2 1.0 Reference
Ex-smoker 5/20 25.0 1.21 (0.32–4.52)
Current smoker 10/66 15.2 0.65 (0.22–1.96)Page 8 of 12
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widely and they are not always significantly different for
infants born to HPV positive or negative mothers.
In a carefully conducted large study [13] the HPV preva-
lence among infants born to HPV-positive women was
4% and among infants born to HPV-negative women was
8%. Consistent with our high rates of HPV X detection,
this study found that all positive results in the infants were
positive for unclassified HPV types and all of them were
preceded or followed by HPV negative specimens. This
report and our data clearly show that the few HPV infec-
tions detected in infants probably represent low-level gen-
ital or non-genital HPVs or may represent horizontal
transmission. Taken together the evidence from this and
other prospective studies [9,10] strongly suggests that the
risk of perinatal transmission of HPVs although existent is
relatively low.
A consistent finding from our cohorts of HPV positive and
negative pregnant women and their offspring is the evi-
dence for horizontal transmission. First, we found that up
to 16.9% of children born to HPV-negative mothers had
HPV infections in the first 24 months of life. This percent-
age is only slightly lower, and not statistically significantly
different, than that observed in infants born to HPV-posi-
tive mothers (19.7%). Secondly, we found an association
between HPV status in the mother at the 6-week postpar-
tum visit and the HPV status in children at the same visit
or thereafter. Thus, at the 6-week post-partum visit, chil-
dren of mothers' who were HPV-positive at the post-par-
tum visit were about 5 times more likely to test HPV-
positive than children of corresponding HPV-negative
mothers (27.3% vs. 7.2%; age-adjusted OR = 4.8; 95% CI,
1.36–16.88; p = 0.02). In contrast, no association was
found between mothers' HPV status at pregnancy and
children's HPV status at any of the visits combined. Thus,
all together, the data in Table 5 indicate that the HPV
detected at the post-partum visit in the mother is a
stronger determinant of HPV infection in the child than
the HPV detected during pregnancy, suggesting that hori-
zontal mother-to-child transmission may play a more
important role than vertical transmission in determining
HPV DNA detection in children. Mothers themselves, rel-
atives, caregivers and fomites harbour HPVs that can be
horizontally transmitted to the child, in particular in the
first weeks of life when there is a close caring physical con-
tact relationship with the infant. Indeed, other study
designs are needed to properly distinguish vertical from
horizontal transmission. These studies should include
accurate and repeated HPV detection and genotyping of
multiple sites from parents, siblings and care givers as well
as assays to distinguish between markers of inert HPV
DNA detection and markers of active HPV infection.
In assessing HPV positivity in children born to HPV-nega-
tive mothers we can not rule out that these mothers were
false HPV negatives at pregnancy. We need to take into
account that 52% of the HPV-negative mothers came from
the high-risk group of women included in the initial
cohort study. Thus, increased HPV exposure may increase
risk of false negative results which might somehow par-
tially explain HPV transmission among HPV-negative
mothers.
Unknown 4/24
Chi-square p-value 0.55
Cytology results at pregnancy
Normal-ASCUS 21/121 17.4 1.0 Reference
LSIL-HSIL 3/17 17.6 1.04 (0.27–3.98)
Unknown 2/5
Chi-square p-value 0.98
Mother's HPV status at pregnancy
Negative 13/77 16.9 1.0 Reference
Positive 13/66 19.7 1.25 (0.53–2.94)
Chi-square p-value 0.66
Mother's HPV status at post-partum visit
Negative 12/93 12.9 1.0 Reference
Positive 8/25 32.0 3.22 (1.14–9.10)
Unknown 6/25
Chi-square p-value 0.02
Mother's HPV status at pregnancy and/or post-partum visit
Negative at both visits 10/65 15.4 1.0 Reference
Positive at either visit 7/43 16.3 1.09 (0.38–3.14)
Positive at both visits 7/24 29.2 2.33 (0.76–7.10)
Unknown 2/11
Chi-square p-value 0.30
Models were adjusted by age group (≤ 28, 29–33, ≥ 34). No association was found with fetal stress at delivery, parity, duration and intensity of 
smoking, child's sex, no. of sex partners before or after 20 years of age or history of genital warts.
Table 4: Selected determinants of HPV DNA detection in children at any time during follow up. (Continued)Page 9 of 12
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ing pregnancy: 6.5% of the unselected group of women
was positive for HPV-DNA by consensus PCR. This rela-
tively low HPV prevalence in pregnant women correlates
with the low prevalence of HPV infection in the female
general population (between 1.3% and 2.4%) [14,15]
and the low incidence rate of cervical cancer in Spain [15].
Still, our HPV prevalence estimate among pregnant
women is between 3 and 5 times higher than that
observed in the female general population, confirming
the findings from other studies showing that pregnant
women do have a higher HPV-DNA detection rate than
un-pregnant women [6,16-18]. It has been argued that
immunological or hormonal changes could modulate the
rate of HPV positivity and clearance during pregnancy
[18,19]. While some authors report evidence that preg-
nancy decreases clearance of high-risk HPV types in the
first two trimesters of pregnancy [16,18,19], others ques-
tion these findings [20,21].
As expected, and consistent with the sexual mode of trans-
mission of HPV infections, we found that an early age at
first sexual intercourse, a high number of sexual partners,
particularly before the age of 20, a previous history of gen-
ital warts or STDs as well as a current squamous intraepi-
thelial lesion in the cervix as diagnosed by cytology, were
the strongest determinants of HPV positivity in pregnant
women (Table 3). These expected associations provide
further internal validity to our complex study.
As shown in Table 4 none of the obstetric variables col-
lected in the study, including cesarean section delivery,
Table 5: Percentage of HPV positive infants at different points during follow-up according to mother's HPV status and specific 
genotypes detected in mother/child HPV positive pairs.
Infants' HPV positivity by follow-up period
Mothers' HPV status at 0 to 6 days at 6 weeks at 3 to 24
months
Any time
(0 to 24 months)
% (HPV+/tested) % (HPV+/tested) % (HPV+/tested) % (HPV+/tested)
At pregnancy
HPV negative 3.1% (2/64) 11.9% (7/59) 7.4% (4/54) 16.9% (13/77)
HPV positive 9.4% (5/53) 13.7% (7/51) 11.8% (4/34) 19.7% (13/66)
Mother/child HPV positive
pairs with concordant
genotypes
[types in mother/child pairs]
1 of 5
[16,6,11/6,11]
2 of 7
[16/16; 18/18]
2 of 4
[16/16; 18/18]
4 of 13
[16,6,11/6,11; 16/16; 16/16; 18/
18]
Mother/child HPV positive
pairs with discordant
genotypes
[types in mother/child pairs]
4 of 5
[18/6,11; X/X; X/X; X/31]
5 of 7
[18/6,11; 18/6,11; X/X; X/X; 
16/X]
2 of 4
[6,11/16; X/X]
9 of 13
[18/6,11; 18/6,11; 6,11/16; X/
31; X/X; X/X; X/X; X/X; X/X]
Fisher's exact test* 0.2 0.8 0.7 0.7
At 6 weeks postpartum
HPV negative 2.7% (2/74) 7.2% (6/83) 6.2% (4/65) 12.9% (12/93)
HPV positive 11.1% (2/18) 27.3% (6/22) 21.4% (3/14) 32.0% (8/25)
Mother/child HPV positive
pairs with concordant
genotypes
[types in mother/child pairs]
0 of 2 2 of 6
[18,6,11/6,11; 18/18]
2 of 3
[18/18; 16,6,11/16]
3 of 8
[18,6,11/6,11; 18/18; 16,6,11/
16]
Mother/child HPV positive
pairs with discordant
genotypes
[types in mother/child pairs]
2 of 2
[16/X; 18/6,11]
4 of 6
[18/6,11; X/X; 16,6,11/X; X/
6,11]
1 of 3
[6,11/16]
5 of 8
[18/6,11; 6,11/16; X/X; 16/X; 
X/6,11]
Fisher's exact test* 0.2 0.02 0.1 0.03
* For the association between HPV status in mother and HPV status in childPage 10 of 12
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:74 http://www.biomedcentral.com/1471-2334/9/74were associated with HPV positivity in children at any
time during follow-up. The effect of cesarean section on
HPV transmission among HPV-positive pregnant women
could not be assessed due to the low number of HPV-pos-
itive children born by cesarean section. Concerning repro-
ductive variables, only ever use of hormonal
contraception was associated with a reduced risk of HPV
in the child. We do not have any biologically plausible
explanation for this inverse association. Since such a rela-
tionship has never before been reported one should be
cautious in its interpretation. Concerning HPV in the
mother the only correlate found for HPV positivity in the
child at any point during follow-up was the mother's HPV
positivity at the post-partum visit. Again, this finding sug-
gests that HPV at the post-partum visit may be more deter-
minant for child's HPV infections than HPV at pregnancy.
It is worth noting that mothers that had HPV status per-
sistence from pregnancy to the post-partum visit had a
higher percentage of HPV-positive children (29.2%) as
compared to mothers negative at the two visits (15.4%) or
HPV positive in only one of the two visits (16.3%). How-
ever, the association did not reach statistical significance
(Table 4).
In interpreting these results it should be considered that our
reported HPV type-specific distribution is probably biased
towards an overestimated detection of HPV X, as the samples
that tested positive with the generic probe were tested with
only seven type-specific probes (HPVs 6,11,16,18,31,33, and
39). Thus the high percentage of samples classified as HPV X
could be true rare genital HPV types, cutaneous types
(unlikely because of the poor efficiency of the primer system
in detecting cutaneous types) or still untyped HPVs. Further-
more the MY09/MY11 primer system has been improved by
the PGMY primer system in terms of higher reproducibility
of primer synthesis as well as detection of mucosal HPVs.
Unfortunately, very few samples remained available for re-
testing with the newer PGMY system. This limitation may
also have resulted in an underestimation of the true underly-
ing type-specific concordance.
In conclusion, our study, conducted in a population at
low risk for HPV and cervical cancer, confirms that high-
risk HPV genotypes can be vertically transmitted to the
child, although the risk of vertical transmission is rela-
tively low. In this study, if we exclude untyped (HPV X)
infections, HPV 16 has been found to be the most fre-
quent type detected both in mothers and infants. Infants
of women who tested HPV positive at six weeks after
delivery are nearly five times more likely to test HPV pos-
itive than infants of HPV-negative mothers. HPV persist-
ence in infants is a rare event. Given the substantial HPV
positivity observed in children born to HPV-negative
mothers, these data suggest that vertical transmission may
not be the sole source of HPV infections in children and
that horizontal mother-to-child transmission may play
also a role. It remains to be seen whether this alternative
mode of HPV transmission and acquisition may have an
impact in several areas, including vaccination strategies,
epidemiological studies, and the clinical management of
children with HPV-associated diseases.
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